Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA238728,10.1186/s12943-023-01884-x,Mol Cancer,37964379,https://pubmed.ncbi.nlm.nih.gov/37964379,"A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better",2023,"Melanoma, CD40, PD-1, Clinical Trial, Csf1r, Checkpoint Inhibition Resistance","Dijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M Kaech, Marcus Bosenberg, Lucia B Jilaveanu, Harriet M Kluger","Background: Stimulating inflammatory tumor associated macrophages can overcome resistance to PD-(L)1 blockade. We previously conducted a phase I trial of cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist) and nivolumab. Our current purpose was to study the activity and cellular effects of this three-drug regimen in anti-PD-1-resistant melanoma. Methods: We employed a Simon's two-stage design a(Read more on Pubmed)",Clinical Study,Melanoma,Not Applicable,Not Applicable,Open Access,37964379,e7ce5a39-d723-4da6-8659-760ba5eb3e85,syn52565390
